Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

被引：7

作者：

Kim, Youn H. ^{[1
]}

Whittaker, Sean ^{[2
]}

Horwitz, Steven M. ^{[3
]}

Duvic, Madeleine ^{[4
]}

Dummer, Reinhard ^{[5
]}

Scarisbrick, Julia J. ^{[6
]}

Quaglino, Pietro ^{[7
]}

Zinzani, Pier Luigi ^{[8
]}

Wolter, Pascal ^{[9
]}

Wang, Yinghui ^{[10
]}

Palanca-Wessels, Maria Corinna ^{[10
]}

Zagadailov, Erin ^{[11
]}

Trepicchio, William L. ^{[11
]}

Liu, Yi ^{[11
]}

Little, Meredith ^{[11
]}

Prince, H. Miles ^{[12
]}

机构：

[1] Stanford Univ, Dept Med, Sch Med, Div Oncol, Stanford, CA 94305 USA

[2] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA

[5] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[6] Univ Hosp Birmingham, Dept Dermatol, Birmingham, W Midlands, England

[7] Univ Turin, Dept Med Sci, Turin, Italy

[8] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy

[9] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[10] Seattle Genet Inc, Seattle, WA USA

[11] Takeda Pharmaceut, Cambridge, MA 02138 USA

[12] Peter MacCallum Canc Ctr, Canc Med, Melbourne, Vic, Australia

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.182.182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

182

引用

页数：8

共 42 条

[11] Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)
Horwitz, Steven M.
Scarisbrick, Julia J.
Dummer, Reinhard
Duvic, Madeleine
Kim, Youn H.
Walewski, Jan
Whittaker, Sean
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Eradat, Herbert
Sanches, Jose A.
Ortiz-Romero, Pablo L.
Akilov, Oleg E.
Trotman, Judith
Taylor, Kerry
Dalle, Stephane
Weichenthal, Michael
Fisher, David C.
Stadler, Rudolf
Feldman, Tatyana A.
Kuzel, Timothy M.
Gru, Alejandro A.
Wang, Yinghui
Palanca-Wessels, Maria Corinna
Lin, Hui-Min
Liu, Yi
Little, Meredith
Prince, H. Miles
BLOOD, 2017, 130
[12] Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities.
Yasenchak, Christopher A.
Bordoni, Rodolfo Eduardo
Yazbeck, Victor Y.
Patel-Donnelly, Dipti
Larson, Tim
Sims, Robert Brownell
Mei, Matthew Genyeh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[13] Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma
Sano, Dahlia
Ahmed, Sairah
Liu, Jingmin
Knowles, Scott
Lee, Seung Tae
BLOOD, 2022, 140 : 12003 - 12004
[14] Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Kim, Youn H.
Prince, H. Miles
Whittaker, Sean
Horwitz, Steven M.
Duvic, Madeleine
Bechter, Oliver
Sanches, Jose A.
Stadler, Rudolf
Scarisbrick, Julia
Quaglino, Pietro
Zinzani, Pier Luigi
Wolter, Pascal
Eradat, Herbert
Pinter-Brown, Lauren C.
Ortiz-Romero, Pablo L.
Akilov, Oleg E.
Trotman, Judith
Taylor, Kerry
Weichenthal, Michael
Walewski, Jan
Fisher, David
McNeeley, Marise
Gru, Alejandro A.
Brown, Lisa
Palanca-Wessels, M. Corinna
Lisano, Julie
Onsum, Matthew
Bunn, Veronica
Little, Meredith
Trepicchio, William L.
Dummer, Reinhard
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 411 - 421
[15] Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma
Hirai, Yoji
Sakurai, Jun
Yoshida, Shiho
Kikuchi, Takashi
Mitsuhashi, Toshiharu
Miyake, Tomoko
Fujimura, Taku
Abe, Riichiro
Fujikawa, Hiroki
Boki, Hikari
Suga, Hiraku
Shibata, Sayaka
Miyagaki, Tomomitsu
Shimauchi, Takatoshi
Kiyohara, Eiji
Kawakami, Yoshio
Morizane, Shin
JOURNAL OF DERMATOLOGY, 2024, 51 (08): : 1037 - 1049
[16] Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30Positive Cutaneous T-Cell Lymphoma
Wang, Qian
Jiang, Ming
Zhang, Chunlei
Wu, Sheng
Jiang, Wenhan
Ji, Meng
Chen, Tong
BLOOD, 2022, 140 : 12044 - 12045
[17] Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician 's choice in cutaneous T-cell lymphoma: final data. (vol 5, pg 5098, 2021)
Horwitz, S. M.
Scarisbrick, J. J.
Dummer, R.
BLOOD ADVANCES, 2024, 8 (09) : 2243 - 2243
[18] A PHASE II STUDY WITH BENDAMUSTINE PLUS BRENTUXIMAB VEDOTIN IN HODGKIN'S LYMPHOMA AND CD30+PERIPHERAL T-CELL LYMPHOMA IN FIRST SALVAGE SETTING: THE BBV REGIMEN
Pellegrini, C.
Botto, B.
Corradini, P.
Pinto, A.
Re, A.
Badiali, S.
Argnani, L.
Vitolo, U.
Zinzani, P. L.
HAEMATOLOGICA, 2017, 102 : 30 - 30
[19] BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T-CELL LYMPHOMA PATIENTS: A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI
Carella, M.
Pellegrini, C.
Corradini, P.
Orsucci, L.
Volpetti, S.
Argnani, L.
Dodero, A.
Stefoni, V.
Zinzani, P. L.
HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
[20] PHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+MATURE T-CELL LYMPHOMAS (MTCL)
Illidge, T.
Pro, B.
Truemper, L. H.
Larsen, E. K.
Huebner, D.
Kennedy, D. A.
O'Connor, O.
ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →